NewsWorldBioNTech, Pfizer vaccine neutralises Omicron with three shots

BioNTech, Pfizer vaccine neutralises Omicron with three shots

BioNTech and Pfizer have said a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test and they could deliver an Omicron-based vaccine in March 2022 if needed.

In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said two vaccine doses resulted in significantly lower neutralising antibodies, but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.

At the same time, the Omicron variant has been reported in 57 nations and the number of patients needing hospitalisation is likely to rise as it spreads, the World Health Organization said on Wednesday.

The WHO, in its weekly epidemiological report, said more data was needed to assess the severity of disease caused by the Omicron variant and whether its mutations might reduce protection from vaccine-derived immunity.

 

Top Stories

Taste